Table 8.

Body fat composition before and after re-installing SGAs in patients with schizophrenia during a 6-week treatment with risperidone depending on the presence or absence of MetS [Me (Q1; Q3)].

Time-point for the assessment	Patients with MetS (n = 15)	p-value	Patients without MetS (n = 28)	p-value
Total body fat percentage
At hospitalization	33.9 [28.9; 41.9]	0.889	27.1 [16.7; 35.7]	0.020*
After a 6-week treatment	33.9 [28.4; 43.2]		29.2 [16.7; 36.1]
Visceral fat level
At hospitalization	10 [8; 12]	0.257	5 [4; 7]	0.068
After a 6-week treatment	10 [8; 12]		5 [3; 7]
Total fat fold
At hospitalization, mm	98 [82; 118]	0.582	74 [45; 88]	0.066
After a 6-week treatment, mm	101 [81; 121]		70 [49; 90]
Waist circumference
At hospitalization, cm	104 [96; 113]	0.538	80 [74; 90]	0.020*
After a 6-week treatment, cm	105 [96; 113]		82 [74; 94]
Body weight
At hospitalization, kg	91.0 [78.0; 99.1]	0.649	71.9 [61; 80.3]	0.002*
After a 6-week treatment, kg	92.9 [78.2; 100.1]		71.9 [63.4; 81.9]
Body mass index
At hospitalization	29.9 [26.5; 31.2]	0.723	23.2 [21.6; 25.8]	0.001*
After a 6-week treatment	30.2 [26.7; 31.8]		23.6 [21.8; 27.5]

*p < 0.05—statistically significant difference. Comparisons between groups were performed using the Wilcoxon signed-rank test.